Navigation Links
Risperdal Lawsuits Mount, With Filing of New Gynecomastia Complaint in New York Federal Court, Bernstein Liebhard LLP Reports
Date:8/2/2014

New York, New York (PRWEB) August 02, 2014

Risperdal lawsuits (http://www.lawreward.com/risperdal-lawsuit/) that allege use of the antipsychotic medication caused men and boys to develop gynecomastia, or male breast growth, continue to mount in U.S. courts, Bernstein Liebhard LLP reports. According to court documents dated July 8th, one such case has been filed in U.S. District Court, Northern District of New York, on behalf of a 21-year-old man who underwent multiple surgeries to remove excess breast tissue after he developed gynecomastia that was allegedly caused by Risperdal. The complaint further claims that the Plaintiff’s treatment with the medication for several years also caused him to begin lactating. The new Risperdal lawsuit seeks compensation for severe, painful, disabling and permanent injuries, as well as emotional problems allegedly endured by the Plaintiff. (Case 1:14-cv-00820-GTS-RFT)

“Our Firm is representing a number of clients whose experience with this medication echo the allegations put forth in this latest Risperdal lawsuit filing,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Gynecomastia Litigation
Court documents indicate that hundreds of plaintiffs are currently pursuing Risperdal lawsuits for gynecomastia allegedly caused by the medication. The majority of these claims are pending in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas. Among other things, the complaints accuse Johnson & Johnson and Janssen of concealing the association between Risperdal and male breast growth, and of improperly marketing the drug for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).

On November 4th, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.5 million to resolve criminal and civil charges stemming from their marketing of Risperdal and other drugs. Among other things, federal prosecutors had alleged that the companies marketed Risperdal for pediatric uses long before it was approved for such indications in 2006. According to court documents filed in the case, the Justice Department had also charged that the company concealed side effects associated with the medication, including an association between Risperdal and male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.lawreward.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb12067205.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Risperdal Meeting Scheduled for August in Pennsylvania Litigation, Bernstein Liebhard LLP Reports
2. Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports
3. New Risperdal Lawsuit Website Published by Bernstein Liebhard LLP; Provides Side Effect Information, Litigation Updates
4. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes New Report Detailing Increasing Use of Risperdal and other Antipsychotic Drugs Among Children
5. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
6. Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies
7. As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
8. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
9. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
10. As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Launches Website to Provide Information Regarding Alleged Association Between Risperdal and Gynecomastia
11. Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, LLC ... Pharmaceutical Specialties, Inc. ("PSI").  The combination of Texas ... Georgia -based PSI bring together both company,s clinical expertise ... and payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
Breaking Medicine Technology: